Protection by group II phospholipase A2 against Staphylococcus aureus

Journal of Immunology

Volumn 162, Issue 12, 1999, Pages 7402-7408

  Laine, Veli J O ^a,b   Grass, David S ^c   Nevalainen, Timo J ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c Chrysalis DNX Transgenic Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST RESISTANCE; IMMUNITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; TRANSGENIC MOUSE;

ANIMALS; BLOOD BACTERICIDAL ACTIVITY; CYTOKINES; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; KIDNEY; LIVER; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, TRANSGENIC; PERITONEAL LAVAGE; PERITONEUM; PHOSPHOLIPASES A; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS;

EID: 0033564947     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lin, L. L., A. Y. Lin, and J. L. Knopf. 1992. Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc. Natl. Acad. Sci. USA 89:6147.
2. Uozumi, N., K. Kume, T. Nagase, N. Nakatani, S. Ishii, F. Tashiro, Y. Komagata, K. Maki, K. Ikuta, Y. Ouchi, J. Miyazaki, and T. Shimizu. 1997. Role of cytosolic phospholipase A2 in allergic response and parturition Nature 390:618.
3. Boventre, J. V., Z. Huang, M. R. Taheri, E. O'Leary, E. Li, M. A. Moskowitz, and A. Sapirstein. 1997. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390:622.
4. Kramer, R. M., D. T. Stephenson, E. F. Roberts, and J. A. Clemens. 1996. Cytosolic phospholipase A2 (cPLA2) and lipid mediator release in the brain. J. Lipid. Mediat. Cell. Signal. 14:3.
5. Crowl, R. M., T. J. Stoller, R. R. Conroy, and C. R. Stoner. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 266:2647.
6. Ogawa, M., H. Arakawa, S. Yamashita, K. Sakamoto, and S. Ikei. 1992. Post-operative elevations of serum interleukin 6 and group II phospholipase A2: group II phospholipase A2 in serum is an acute phase reactant. Res. Commun. Chem. Pathol. Pharmacol. 75:109.
7. Rintala, E. M., and T. J. Nevalainen. 1993. Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections. Clin. Infect. Dis. 17:864.
8. Green, J. A., G. M. Smith, R. Buchta, R. Lee, K. Y. Ho, I. A. Rajkovic, and K. F. Scott. 1991. Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis. Inflammation 15:355.
9. Nyman, K. M., W. Uhl, J. Forsström, M. Büchler, H. G. Beger, and T. J. Nevalainen. 1996. Serum phospholipase A2 in patients with multiple organ failure. J. Surg. Res. 60:7.
10. Vadas, P., and W. Pruzanski. 1993. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ. Shock 39:160.
11. Grass, D. S., R. H. Felkner, M. Y. Chiang, R. E. Wallace, T. J. Nevalainen, C. F. Bennett, and M. E. Swanson. 1996. Expression of human group II PLA2 in transgenic mice results in epidermal hyperplasia in the absence of inflammatory infiltrate. J. Clin. Invest. 97:2233.
12. Kennedy, B. P., P. Payette, J. Mudgett, P. Vadas, W. Pruzanski, M. Kwan, C. Tang, D. E. Rancourt, and W. A. Cromlish. 1995. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J. Biol. Chem. 270:22378.
13. Nevalainen, T. J., P. T. Kortesuo, E. Rintala, and F. Märki. 1992. Immunochemical detection of group I and group II phospholipases A2 in human serum. Clin. Chem. 38:1824.
14. Weinrauch, Y., P. Elsbach, L. M. Madsen, A. Foreman, and J. Weiss. 1996. The potent anti-Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. J. Clin. Invest. 97:250.
15. Eskola, J. U., T. J. Nevalainen, and P. Kortesuo. 1988. Immunoreactive pancreatic phospholipase A2 and catalytically active phospholipases A2 in serum from patients with acute pancreatitis. Clin. Chem. 34:1052.
16. Haapamäki, M. M., J. M. Grönroos, H. Nurmi, K. Alanen, M. Kallajoki, and T. J. Nevalainen. 1997. Gene expression of group II phospholipase A2 in intestine in ulcerative colitis. Gut 40:95.
17. Di Marco, S., F. Märki, H. Hofstetter, A. Schmitz, J. van Oostrum, and M. G. Grütter. 1992. Purification, analysis, and enzymatic activity of recombinant human synovial fluid phospholipase A2 and N-terminal variants. J. Biochem (Tokyo) 112:350.
18. Laine, V. J. O., K. M. Nyman, H. J. Peuravuori, K. Henriksen, M. Parvinen, and T. J. Nevalainen. 1996. Lipopolysaccharide induced apoptosis of rat pancreatic acinar cells. Gut 38:747.
19. Schädlich, H. R., M. Büchler, and H. G. Beger. 1987. Improved method for the determination of phospholipase A2 catalytic activity concentration in human serum and ascites. Eur. J. Clin. Chem. Clin. Biochem. 25:505.
20. Guidet, B., O. Piot, J. Masliah, V. Barakett, E. Maury, G. Bereziat, and G. Offenstadt. 1996. Secretory non-pancreatic phopholipase A2 in severe sepsis: relation to endotoxin, cytokines and thromboxane B2. Infection 24:103.
21. Keuter, M., E. Dharmana, B. J. Kullberg, C. Schalkwijk, M. H. Gasem, L. Seuren, R. Djokomoeljanto, W. M. Dolmans, H. van den Bosch, and J. W. van der Meer. 1995. Phospholipase A2 is a circulating mediator in typhoid fever. J. Infect. Dis. 172:305.
22. Weinrauch, Y., C. Abad, N.-S. Liang, S. F. Lowry, and J. Weiss. 1998. Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. J. Clin. Invest. 102:633.
23. Weiss, J., M. Inada, P. Elsbach, and R. M. Crowl. 1994. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J. Biol. Chem 269: 26331.
24. Páramo, L., B. Lomonte, J. Pizarro-Cerdá, J.-A. Bengoechea, J.-P. Grovel, and E. Moreno. 1998. Bactericidal activity of Lys49 and Asp49 myotoxic phospholipases A2 from Bothrops asper snake venom. Eur. J. Biochem. 253:452.
25. Qu, X. D., and R. I. Lehrer. 1998. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Neurochem. Res. 23-807.
26. Madsen, L. M., M. Inada, and J. Weiss. 1996. Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli. Infect. Immun. 64:2425.
27. Laine, V. J. O., D. S. Grass, and T. J. Nevalainen. 1997. Resistance of transgenic mice expressing human group II phospholipase A2 to E. coli infection. Shock 7:24.
28. Nevalainen, T. J., V. J. O. Laine, and D. S. Grass. 1997. Expression of human group II phospholipase A2 in transgenic mice. J. Histochem. Cytochem. 45:1109.
29. Vadas, P., W. Pruzanski, E. Stefanski, L. G. Ellies, J. E. Aubin, A. Sos, and A. Melcher. 1991. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. Immunol. Lett. 28:187.
30. Ozaki, Y., T. Ohashi, A. Minami, and S.-I. Nakamura. 1987. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1α. Infect. Immun. 55:1436.
31. Minami, A., K. Fujimoto, Y. Ozaki, and S. Nakamura. 1988. Augmentation of host resistance to microbial infections by recombinant human interleukin-1α. Infect. Immun. 56:3116.
32. van der Meer, W. M., M. Barza, S. M. Wolff, and C. A. Dinarello. 1988. A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal Gram-negative infection. Proc. Natl. Acad. Sci. USA 85:1620.
33. van der Meer, J. W. 1989. Options for the treatment of serious infections with interleukin-1. Biotherapy 1:313.
34. van der Meer, J. W., M. T. Vogels, and B. J. Kullberg. 1994. Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy 7:161.
35. Williams, D. M., D. M. Magee, L. F. Bonewald, J. G. Smith, C. A. Bleicker, G. I. Byrne, and J. Schachter. 1990. A role in vivo for tumor necrosis factor α in host defense against Chlamydia trachomatis. Infect. Immun. 58:1572.
36. Malaviya, R., T. Ikeda, E. Ross, and S. N. Abraham. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 381:77.
37. Takashima, K., K. Tateda, T. Matsumoto, Y. Iizawa, M. Nakao, and K. Yamaguchi. 1997. Role of tumor necrosis factor α in pathogenesis of pneumococcal pneumonia in mice. Infect. Immun. 65:257.
38. Nishikawa, S., T. Miura, S. Sasaki, and A. Nakane. 1996. The protective role of endogenous cytokines in host resistance against an intragastric infection with Listeria monocytogenes in mice. FEMS Immunol. Med. Microbiol. 16:291.
39. Dalrymple, S. A., R. Slattery, D. M. Aud, M. Krishna, L. A. Lucian, and R. Murray. 1996. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect. Immun. 64:3231.
40. Dalrymple, S. A., L. A. Lucian, R. Slattery, T. McNeil, D. M. Aud, S. Fuchino, F. Lee, and R. Murray. 1995. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect. Immun. 63:2262.
41. van der Poll, T., C. V. Keogh, X. Guirao, W. A. Buurman, M. Kopf, and S. F. Lowry. 1997. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 176:439.
42. Williams, D. M., B. G. Grubbs, T. Darville, K. Kelly, and R. K. Rank. 1998. A role for interleukin-6 in host defense against murine Chlamydia trachomatis infection. Infect. Immun. 66:4564.
43. + T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 183:1345.
44. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias. 1996. Immune and inflammatory responses in TNFα-deficient mice: a critical requirement for TNFα in the formation of primary follicles, follicular dendritic cell networks and germinal centres, and in the maturation of the humoral immune response. J. Exp. Med. 184:1397.
45. Zheng, H., D. Fletcher, W. Kozak, M. Jiang, K. J. Hofmann, C. A. Conn, D. Soszynski, C. Grabiec, M. E. Trumbauer, A. Shaw, et al. 1995. Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice. Immunity 3:9.
46. Solorzano, C. C., R. Ksontini, J. H. Pruitt, T. Auffenberg, C. Tannahill, R. E. Galardy, G. P. Schultz, S. L. MacKay, E. M. Copeland III, and L. L. Moldawer. 1997. A matrix metalloproleinase inhibitor prevents processing of tumor necrosis factor α (TNFα) and abrogates endotoxin-induced lethality. Shock 7:427.
47. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662.
48. Tracey, K. J. 1991. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circ. Shock 35:123.
49. Gabay, J. E. 1994. Ubiquitous natural antibiotics. Science 264:373.
50. Fearon, D. T. 1997. Seeking wisdom in innate immunity. Nature 388:323.
51. Ganz, T., and J. Weiss. 1997. Antimicrobial peptides of phagocytes and epithelia. Semin. Hematol. 34:343.